CPRX
Catalyst Pharmaceuticals, Inc.NASDAQHealthcare$24.69-0.52%ClosedMarket Cap: $3.03B
As of 2026-04-06
Valuation
P/E (TTM)
14.16
PEG
0.46
P/B
3.20
P/S
5.21
EV/EBITDA
7.55
DCF Value
$158.90
FCF Yield
6.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.2%
Operating Margin
43.8%
Net Margin
36.4%
ROE
24.3%
ROA
19.4%
ROIC
20.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $152.6M | 90.8% | $61.8M | $52.7M | $0.40 | — |
| FY 2025 | $589.0M | 85.2% | $257.8M | $214.3M | $1.68 | — |
| Q3 2025 | $148.4M | 82.9% | $66.3M | $52.8M | $0.42 | — |
| Q2 2025 | $146.6M | 79.6% | $66.3M | $52.1M | $0.41 | — |
| Q1 2025 | $141.4M | 87.3% | $63.4M | $56.7M | $0.45 | — |
| Q4 2024 | $141.8M | 84.7% | $62.8M | $55.9M | $0.44 | — |
| FY 2024 | $491.7M | 86.0% | $195.1M | $163.9M | $1.31 | — |
| Q3 2024 | $128.7M | 85.0% | $50.9M | $43.9M | $0.35 | — |
| Q2 2024 | $122.7M | 87.4% | $54.2M | $40.8M | $0.33 | — |
| Q1 2024 | $98.5M | 87.3% | $27.1M | $23.3M | $0.19 | — |
| Q4 2023 | $110.6M | 85.7% | $41.7M | $34.8M | $0.31 | — |
| FY 2023 | $398.2M | 86.9% | $86.8M | $71.4M | $0.63 | — |